HLNE
Hamilton Lane Incorporated
HLNE's fundamentals are strong: its operating margin rose 11 points to 54% and revenue grew 19%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
HLNE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| N/A | |
| N/A |
HLNE's revenue and profitability are currently strong. Free cash flow and net leverage aren't meaningful measures for financial services companies like HLNE.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
HLNE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $93.88 | — |
| Current | 14x | $93.88 | — |
| Cheap | 17x | $116 | +24% |
| Fair | 27x | $179 | +91% |
| Expensive | 37x | $249 | +165% |
Historical ranges are pointers, not guarantees.
HLNE's PE is 14x, but its earnings don't support one, so it isn't a reliable read right now.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
HLNE Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
HLNE has the edge over IREN on the outlook, with more favorable earnings expectations.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IREN's losses to grow, with revenue growing. However, they disagree widely on these estimates.
HLNE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.30 | +8.4% |
| Q3 2026 | $6.74 | +22% |
| Q2 2026 | $6.56 | +26% |
| Q1 2026 | $5.91 | +9.6% |
| Q4 2025 | $5.57 | +1.6% |
| Q4 2021 | $4.59 | +89% |
| Q3 2021 | $4.15 | +115% |
| Q2 2021 | $3.40 | +86% |
| Q1 2021 | $2.73 | +28% |
HLNE has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
HLNE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $204.4M | +7.1% |
| Q2 2026 | $275.3M | +56% |
| Q1 2026 | $193.6M | -2.2% |
| Q4 2025 | $198.6M | +18% |
| Q3 2025 | $190.9M | +27% |
| Q2 2025 | $176M | -11% |
| Q1 2025 | $198M | +18% |
| Q2 2024 | $196.7M | +57% |
HLNE's revenue is growing: $204M last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 87% | +46 points |
| Q2 2026 | 46% | +2.2 points |
| Q1 2026 | 42% | 0 points |
| Q4 2025 | 43% | -1.7 points |
| Q3 2025 | 42% | -3 points |
| Q2 2025 | 44% | -1.8 points |
| Q1 2025 | 42% | -2.5 points |
| Q4 2024 | 45% | N/A |
HLNE has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN has the edge over HLNE on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
HLNE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $22.8M | -81% |
| Q2 2026 | $98.9M | -22% |
| Q1 2026 | $101.2M | +182% |
| Q4 2025 | $72.4M | +23% |
| Q3 2025 | $120.1M | +3.7% |
| Q2 2025 | $127.6M | +63% |
| Q1 2025 | $35.8M | +78% |
| Q2 2024 | $78.2M | 0% |
HLNE has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
HLNE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +1.3M shares |
| 1 year | +2.3% | +1.3M shares |
| 3 years | +3.8% | +2M shares |
| 5 years | +60% | +21M shares |
| Available history | +88% | +26.1M shares |
HLNE has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $50.6M |
| Q1 2026 | $23.2M |
| Q4 2025 | $595,000 |
| Q3 2025 | $835,000 |
| Q2 2025 | $7,000 |
| Q1 2025 | $252.9M |
| Q4 2024 | $72,000 |
| Q3 2024 | $391,000 |
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
HLNE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.1x | Very low |
HLNE has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like HLNE.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
HLNE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 31.1 | Neutral |
HLNE's weekly RSI is 51 (neutral) and its Stochastic is 31 (neutral).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
HLNE PE vs Financial Services Sector
| Metric | HLNE | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 7% above |
| PE % | 4 | 63 | 59 pts below |
HLNE is trading at 14x earnings, in line with the Financial Services sector's median of 13x, though its earnings don't support one.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
HLNE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $86.3 | 8.8% above |
| 20 week MA | $90.6 | 3.6% above |
| 50 week MA | $101.7 | 7.7% below |
| 100 week MA | $123.8 | 24% below |
| 200 week MA | $117.2 | 20% below |
HLNE has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
HLNE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.2 | $78.7 | +29% |
| 2021 | $78.7 | $103.7 | +32% |
| 2022 | $103.7 | $65.5 | -37% |
| 2023 | $65.5 | $113.4 | +73% |
| 2024 | $113.4 | $151.6 | +34% |
| 2025 | $151.6 | $138.5 | -8.6% |
| 2026 YTD | $138.5 | $93.9 | -32% |
HLNE has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.